Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test

Behavioural Pharmacology

Volumn 8, Issue 2-3, 1997, Pages 196-215

  Sams Dodd, F ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antipsychotics; Negative symptoms; Phencyclidine; Positive symptoms; Rat; Schizophrenia; Social behaviour

Indexed keywords

NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; PHENCYCLIDINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SPECIFICITY; MALE; NEGATIVE SYNDROME; NONHUMAN; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL ISOLATION; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; IMIDAZOLES; INDOLES; INTERPERSONAL RELATIONS; MALE; PHENCYCLIDINE; PIRENZEPINE; RATS; RATS, WISTAR; REMOXIPRIDE; SOCIAL ISOLATION; STEREOTYPIC MOVEMENT DISORDER;

EID: 0030844332     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Ban TA, Lohrenz JJ and Lehmann HE (1961) Observations on the action of sernyl - a new psychotropic drug. Canadian Psychiatric Association Journal, 6, 150-157.
2. Beasley Jr CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, Olanzapine HGAP Study Group (1996) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124, 159-167.
3. Bodi T, Share I, Levy H and Moyer JH (1959) Clinical trials of phencyclidine (sernyl) in patients with psychoneurosis. Antibiotic Medicine and Clinical Therapy, 6, 79-84.
4. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A and Carpenter WT (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20-26.
5. Bunny BS and Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sciences, 23, 1715-1728.
6. Carman J, Peuskens J and Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. International Clinical Psychopharmacology, 10, 207-213.
7. Casey DE (1996) 'Seroquel' (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Expert Opinion on Investigational Drugs, 5, 939-957.
8. Castellani S and Adams PM (1981) Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. European Journal of Pharmacology, 73, 143-154.
9. Chiodo LA and Bunny BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Journal of Neuroscience, 3, 1607-1619.
10. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L and Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25-39.
11. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K and Dunn RW (1995) Antipsychotic agents antagonize non-competetive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology, 120, 67-74.
12. Davies BM and Beech HR (1960) The effects of 1-arylcyclohexylamine (sernyl) on twelve normal volunteers. Journal of Mental Science, 106, 912-914.
13. Eriksson L (1994) Remoxipride in the treatment of psychoses. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18, 619-623.
14. File SE (1980) The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. Journal of Neuroscience Methods, 2, 219-238.
15. Garey RE, McQuitly S, Tootle C and Heath RG (1980) The effects of apomorphine and haldol on PCP induced behavioral and motor abnormalities in the rat. Life Sciences, 26, 277-284.
16. Gerbaldo H, Helisch A, Schneider B, Philipp M and Benkert O (1994) Subtypes of negative symptoms: the primary subtype in schizophrenic and non-schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18, 311-320.
17. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity. a hypothesis for the etiology of schizophrenia. Neuroscience, 41, 1-24.
18. Grant S and Fitton A (1994) Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs, 48, 253-273.
19. Greifenstein FE, Yoshitake J, DeValut M and Gajewski JE (1958) A Study of 1-aryl cyclo hexyl amine for anesthesia. Anesthesia and Analgesia, 37, 283-294.
20. Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. Journal of Neural Transmission, 89, 1-10.
21. Hoffman DC and Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology, 120, 123-133.
22. Holm A-C, Edsman I, Lundberg T and Odlind B (1993) Tolerability of remoxipride in the long term treatment of schizophrenia. Drug Safety, 8, 445-456.
23. Huitema BE (1980) The analysis of corariants and alternatives. Wiley and Sons, New York.
24. Itil T, Keskiner A, Kiremitci N and Holden JMC (1967) Effect of phencyclidine in chronic schizophrenics. Canadian Psychiatric Association Journal, 12, 209-212.
25. Jackson DM, Johansson C, Lindgren LM and Bengtson A (1994) Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacology Biochemistry and Behavior, 41, 465-471.
26. Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 1301-1308.
27. Kahn J-P, Laxenaire M, Burnat G, Albaret C and Holm A-C (1994) Remoxipride in acute psychosis: intramuscular followed by oral treatment compared to haloperidol, a double-blind, multicenter trial. Human Psychopharmacology, 9, 79-92.
28. Kane J, Honigfeld G, Singer J and Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 49, 789-796.
29. Kerwin R and Taylor D (1996) New antipsychotics. A review of their current status and clinical potential. CNS Drugs, 6, 71-82.
30. Klieser E, Strauss WH and Lemmer W (1994) The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiatrica Scandinavica, 89, 68-73.
31. Levy L, Cameron DE and Aitken RCB (1960) Observation on two psychotomimetic drugs of piperidine derivation CI 395 (Sernyl) and CI 400. American Journal of Psychiatry, 116, 843-845.
32. Lindström E, Eriksson B, Hellgren A, von Knorring L and Eberhard G (1995) Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clinical Therapeutics, 17, 402-412.
33. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS and Kelley R (1959) Study of a new schizophrenomimetic drug sernyl. American Medical Associations Archives of Neurology and Psychiatry, 81, 363-369.
34. Marder SR and Meibach RC (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
35. McLaren S, Cookson JC and Silverstone T (1992) Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. International Clinical Psychopharmacology, 7, 67-72.
36. Meltzer HY, Alphs LD, Bastani B, Ramirez LF and Kwon K (1991) Clinical efficacy of clozapine in the treatment of schizophrenia. Pharmacopsychiatry, 24, 44-45.
37. Migler, BM, Warawa EJ and Malick JB (1993) Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacologgy, 112, 299-307.
38. Moore NA, Calligaro DO, Wong DT, Bymaster F and Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigation Drugs, 2, 281-293.
39. Morpurgo C and Theobald W (1964) Influence of antiparkinson drugs and amphetamine on some pharmacological effects of phenothiazine derivatives used as neuroleptics. Psychopharmacologia, 6, 178-191.
40. Murray TF and Horita A (1979) Phencyclidine-induced stereotyped behavior in rats: dose response effects and antagonism by neuroleptics. Life Sciences, 24, 2217-2226.
41. Owens DGC (1996) Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs, 51, 895-930.
42. Raskin A, Pelchat R, Sood R, Alphs LD and Levine J (1993) Negative symptoms: assessment of chronic schizophrenia patients. Schizophrenia Bulletin, 19, 627-635.
43. Sams-Dodd F (1995a) Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behavioural Pharmacology, 6, 55-65.
44. Sams-Dodd F (1995b) Automation of the social interaction test by a video tracking system: behavioural effects of repeated phencyclidine treatment. Journal of Neuroscience Methods, 59, 157-168.
45. Sams-Dodd F (1996) Phencyclidine-induced stereotyped behaviour and social isolation in the rat: a possible animal model of schizophrenia. Behavioural Pharmacology, 7, 3-23.
46. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembøl HL, Meier E, Perregaard J and Skarsfeldt T (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Development Research, 22, 239-250.
47. Siegel RK (1978) Phencyclidine and ketamine intoxication a study of 4 populations of recreational users. In: National Institute of Drug Abuse Research Monograph # 21 (Eds RC Peterson and RC Stillman), pp. 119-147. NIH Press, Washington DC.
48. Skarsfeldt T (1992) Electrophysiological profile of the new-atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse, 10, 25-33.
49. Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. European Journal of Pharmacology, 281, 289-294.
50. Steinpreis RE, Sokolowski JD, Papanikolaou A and Salamone JD (1994) The effects of haloperidole and clozapine on PCP-and amphetamine-induced suppression of social behavior in the rat. Pharmacology, Biochemistry and Behavior, 47, 579-585.
51. Sturgeon RD, Fessier RG and Meltzer HY (1979) Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behaviour and ataxia in rats. European Journal of Pharmacology, 59, 169-179.
52. Tamminga CA and Lahti AC (1996) The new generation of antipsychotic drugs. International Clinical Psychopharmacology, 11, 73-76.
53. Van Kammen DP, McEnvoy JP, Targum SD, Kardatzke D, Sebree TB and Sertindole Study Group (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology, 124, 168-175.
54. Wetzel H, Szegedi A, Hain CH, Wiesner J, Schlegel S and Benkert O (1995) Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology, 119, 231-238.
55. Zimbroff DL, Mack RJ, Zborowski J, Morris DD, Sebree TB and Wallin BA (1996) The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. New Research Section 543 presented at the American Psychiatric Association annual meeting, New York, NY.